ReviewFrontiers in genetics2019
Potential Adverse Cardiovascular Effects of Treatment With Fluoxetine and Other Selective Serotonin Reuptake Inhibitors (SSRIs) in Patients With Geriatric Depression: Implications for Atherogenesis and Cerebromicrovascular Dysregulation.
Review in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Inhibition of the serotonin transporter and risk of heart valve disease: A systematic review and meta-analysis.European journal of pharmacology · 2026Pooled it
- Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.BMC psychiatry · 2021Trial
- Atherosclerosis risk and clinical correlates in first-episode drug-naïve patients with major depressive disorder: a large-scale cross-sectional study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- The Impact of Cognitive Impairment on Cardiovascular Disease.Journal of the American College of Cardiology · 2025Review
- Identifying Predictors of Serious Adverse Events in Antidepressant Treatment from a Decade-Long Nationwide Pharmacovigilance Study: Impact of Dementia and Parkinson's Disease Treatment.Medicina (Kaunas, Lithuania) · 2025Article
- Effects of selective serotonin reuptake inhibitor (SSRI) use on cardiometabolic health and risk in young healthy individuals: A preliminary matched pairs study.Physiological reports · 2025Article
- Depressive Symptoms Can Attenuate Rehabilitation Effects in Fracture Patients.Progress in rehabilitation medicine · 2025Article
- Article
- Astrocyte-derived dominance winning reverses chronic stress-induced depressive behaviors.Molecular brain · 2024Article
- Pharmacokinetics and Pharmacodynamics: A Comprehensive Analysis of the Absorption, Distribution, Metabolism, and Excretion of Psychiatric Drugs.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Value of Chuanjin Qinggan decoction in improving the depressive state of patients with herpes zoster combined with depression.World journal of psychiatry · 2023Article
- Pre-intensive care unit use of selective serotonin reuptake inhibitors and mortality in critically ill adults with mental disorders: analysis from the MIMIC-IV database.Translational psychiatry · 2023Article
- Posttraumatic Stress Disorder as a Consequence of Acute Cardiovascular Disease.Current cardiology reports · 2023Review
- Therapeutic Potential of the Purinergic System in Major Depressive Disorder Associated with COVID-19.Cellular and molecular neurobiology · 2023Review
- Current Insights into Treating Vertigo in Older Adults.Drugs & aging · 2021Review
- Risk factors for natural cause mortality in a cohort of 1494 persons with serious mental illness.Psychiatry research · 2021Article
- The effect of fluoxetine combined with repetitive transcranial magnetic stimulation on the psychological emotions and cognitive and neurological functions of acute post-stroke depression patients.American journal of translational research · 2021Article
- The Possible Ameliorating Role of Fisetin on Hepatic Changes Induced by Fluoxetine in Adult Male Albino Rats: Histological, Immunohistochemical, and Biochemical Study.Journal of microscopy and ultrastructureArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Late life depression is an important public health problem, which associates with increased risk of morbidity and mortality. Selective serotonin reuptake inhibitors (SSRIs), including fluoxetine, are often prescribed to treat geriatric depression. There is increasing evidence that fluoxetine and other SSRIs exert a wide range of cardiovascular side effects. Furthermore, there is evidence that aging may increase plasma level of SSRIs. In this overview, the potential role of side effects of treatment with fluoxetine and other SSRIs in the pathogenesis of age-related cardiovascular diseases, including atherogenesis, cardiac pathologies, and cerebromicrovascular impairment, is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.